本帖最后由 老马 于 2012-1-13 21:20 编辑 ( ~) _; X; C" ~0 I4 z
$ J1 e+ ~+ o! g) h- {+ i" L
爱必妥和阿瓦斯丁的比较& U. H7 C, F: o
$ U; H7 R5 P$ X% N, h0 S0 Chttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/! Q/ [' Q1 m4 u4 ~$ n
9 r7 f+ {: s" U
6 a* V8 h: B/ l, S$ P& s* ~
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
# x. }, u4 w9 K d! I; Y==================================================
$ L* m7 J! e K% d3 t9 ^4 x6 p+ SOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
7 O2 Z, J0 F1 s" nPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.+ q3 i2 @- ` [; [# P
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
2 v1 t/ v& s- o' q5 I& R
|